Relationship of Plasma Cell Infiltration Rates with F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma

Overview

Journal Mol Imaging Radionucl Ther

Date 2025 Feb 7

PMID 39918004

Authors

Ozge Ulas Babacan

Zekiye Hasbek

Hatice Terzi

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to evaluate the relationship between the degree of bone marrow involvement, hematological parameters, and F-fluorodeoxyglucose (F-FDG)-positron emission tomography/computed tomography (PET/CT) data in patients diagnosed with multiple myeloma.

Methods: A total of 71 patients [19 females, 52 males, mean age 67 (36-83) years] who were diagnosed with multiple myeloma between 2014 and 2021, had not received any treatment yet, and underwent F-FDG-PET/CT for staging were included in the study.

Results: No significant correlation was observed between bone marrow standardized uptake value (SUV) and plasma cell infiltration (p=0.07). However, we found that patients with visually increased bone marrow counts also had higher plasma cell infiltration rates (p=0.037). No significant correlation was found between plasma cell infiltration rates and bone marrow SUV and systemic inflammatory index (SII) (p=0.187 and p=0.446, respectively). However, there was a significant correlation between the SUV of lytic lesions showing increased F-FDG uptake in bone and SII (p=0.025, r=0.330).

Conclusion: We believe that F-FDG PET/CT may be an advantage over bone marrow biopsy in the diagnosis and evaluation of multiple myeloma recurrence and may prevent repeated bone marrow biopsies.

References

Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X . Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2016; 8(12):18792-18801. PMC: 5386647. DOI: 10.18632/oncotarget.13320. View

Kazandjian D . Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2017; 43(6):676-681. PMC: 5283695. DOI: 10.1053/j.seminoncol.2016.11.004. View

Callander N, Baljevic M, Adekola K, Anderson L, Campagnaro E, Castillo J . NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022; 20(1):8-19. DOI: 10.6004/jnccn.2022.0002. View

Sager S, Ergul N, Ciftci H, Cetin G, Izmir Guner S, Cermik T . The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiol. 2011; 40(7):843-7. DOI: 10.1007/s00256-010-1088-9. View

Ak I, Gulbas Z . F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Ann Hematol. 2010; 90(1):81-7. DOI: 10.1007/s00277-010-1037-7. View

Kim D, Yu E, Kang K, Lee S, Park Y, Sung H . Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. Korean J Intern Med. 2016; 32(4):711-721. PMC: 5511937. DOI: 10.3904/kjim.2016.054. View

Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V . ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2014; 15(1):1-18. DOI: 10.1007/s10238-014-0308-3. View

Firth J . Haematology: multiple myeloma. Clin Med (Lond). 2019; 19(1):58-60. PMC: 6399642. DOI: 10.7861/clinmedicine.19-1-58. View

Dong X, Wang R, Ying X, Xu J, Yan J, Xu P . Construction and validation of an F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients. Hematology. 2024; 29(1):2329029. DOI: 10.1080/16078454.2024.2329029. View

10.

Cengiz A, Arda H, Doger F, Yavasoglu I, Yurekli Y, Bolaman A . Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma. Turk J Haematol. 2018; 35(3):175-180. PMC: 6110447. DOI: 10.4274/tjh.2017.0372. View

11.

Raab M, Cavo M, Delforge M, Driessen C, Fink L, Flinois A . Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016; 175(1):66-76. DOI: 10.1111/bjh.14193. View

12.

Beyer T, Townsend D, Blodgett T . Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med. 2002; 46(1):24-34. View

13.

Zhang L, Chen S, Wang W, Wang Y, Liang Y . Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma. J Inflamm Res. 2023; 16:7-17. PMC: 9831084. DOI: 10.2147/JIR.S390279. View

14.

Nanni C, Zamagni E . Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging. 2017; 44(Suppl 1):111-117. DOI: 10.1007/s00259-017-3730-4. View

15.

Liu S, Shi J, Guo H, Xu F, Wei M, Sun K . Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era. Cancer Manag Res. 2019; 11:9409-9420. PMC: 6842606. DOI: 10.2147/CMAR.S227671. View

16.

Cowan A, Allen C, Barac A, Basaleem H, Bensenor I, Curado M . Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4(9):1221-1227. PMC: 6143021. DOI: 10.1001/jamaoncol.2018.2128. View